Profound Medical (NASDAQ:PROF) Upgraded to “Buy” at Stifel Nicolaus

Stifel Nicolaus upgraded shares of Profound Medical (NASDAQ:PROF – Free Report) from a hold rating to a buy rating in a research report report published on Tuesday morning, MarketBeat Ratings reports. The brokerage currently has $12.00 price objective on the stock, up from their previous price objective of $9.00. Profound Medical Price Performance Shares of […]

Leave a Reply

Your email address will not be published.

Previous post Vista Outdoor (NYSE:VSTO) Coverage Initiated at StockNews.com
Next post Pivetta achieves rare feat against Ohtani but Dodgers hand Red Sox bullpen a brutal loss